Literature DB >> 23804523

Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1.

Arne Meyer1, Anna Vuorinen, Agnieszka E Zielinska, Petra Strajhar, Gareth G Lavery, Daniela Schuster, Alex Odermatt.   

Abstract

Bupropion is widely used for treatment of depression and as a smoking-cessation drug. Despite more than 20 years of therapeutic use, its metabolism is not fully understood. While CYP2B6 is known to form hydroxybupropion, the enzyme(s) generating erythro- and threohydrobupropion have long remained unclear. Previous experiments using microsomal preparations and the nonspecific inhibitor glycyrrhetinic acid suggested a role for 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) in the formation of both erythro- and threohydrobupropion. 11β-HSD1 catalyzes the conversion of inactive glucocorticoids (cortisone, prednisone) to their active forms (cortisol, prednisolone). Moreover, it accepts several other substrates. Here, we used for the first time recombinant 11β-HSD1 to assess its role in the carbonyl reduction of bupropion. Furthermore, we applied human, rat, and mouse liver microsomes and a selective inhibitor to characterize species-specific differences and to estimate the relative contribution of 11β-HSD1 to bupropion metabolism. The results revealed 11β-HSD1 as the major enzyme responsible for threohydrobupropion formation. The reaction was stereoselective and no erythrohydrobupropion was formed. Human liver microsomes showed 10 and 80 times higher activity than rat and mouse liver microsomes, respectively. The formation of erythrohydrobupropion was not altered in experiments with microsomes from 11β-HSD1-deficient mice or upon incubation with 11β-HSD1 inhibitor, indicating the existence of another carbonyl reductase that generates erythrohydrobupropion. Molecular docking supported the experimental findings and suggested that 11β-HSD1 selectively converts R-bupropion to threohydrobupropion. Enzyme inhibition experiments suggested that exposure to bupropion is not likely to impair 11β-HSD1-dependent glucocorticoid activation but that pharmacological administration of cortisone or prednisone may inhibit 11β-HSD1-dependent bupropion metabolism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804523      PMCID: PMC3876805          DOI: 10.1124/dmd.113.052936

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  52 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Novel enzymological profiles of human 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  M Hult; C S Nobel; L Abrahmsen; D A Nicoll-Griffith; H Jörnvall; U C Oppermann
Journal:  Chem Biol Interact       Date:  2001-01-30       Impact factor: 5.192

3.  Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1.

Authors:  Arne Meyer; Anna Vuorinen; Agnieszka E Zielinska; Thierry Da Cunha; Petra Strajhar; Gareth G Lavery; Daniela Schuster; Alex Odermatt
Journal:  Biochem Pharmacol       Date:  2013-02-16       Impact factor: 5.858

4.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Authors:  Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

5.  Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen.

Authors:  Edmund Maser; Jutta Friebertshäuser; Bernhard Völker
Journal:  Chem Biol Interact       Date:  2003-02-01       Impact factor: 5.192

Review 6.  Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.

Authors:  Hiroaki Masuzaki; Jeffrey S Flier
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

7.  Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.

Authors:  Sanna Palovaara; Olavi Pelkonen; Jouko Uusitalo; Stefan Lundgren; Kari Laine
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

8.  Bupropion in depression. II. The role of metabolites in clinical outcome.

Authors:  R N Golden; C L De Vane; S C Laizure; M V Rudorfer; M A Sherer; W Z Potter
Journal:  Arch Gen Psychiatry       Date:  1988-02

Review 9.  11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.

Authors:  Laura L Gathercole; Gareth G Lavery; Stuart A Morgan; Mark S Cooper; Alexandra J Sinclair; Jeremy W Tomlinson; Paul M Stewart
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

10.  Hexose-6-phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids.

Authors:  Lyubomir G Nashev; Charlie Chandsawangbhuwana; Zoltan Balazs; Atanas G Atanasov; Bernhard Dick; Felix J Frey; Michael E Baker; Alex Odermatt
Journal:  PLoS One       Date:  2007-06-27       Impact factor: 3.240

View more
  11 in total

1.  Metabolism of bupropion by carbonyl reductases in liver and intestine.

Authors:  Jamie N Connarn; Xinyuan Zhang; Andrew Babiskin; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2015-04-22       Impact factor: 3.922

2.  Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.

Authors:  Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-09-03       Impact factor: 3.922

3.  Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.

Authors:  Aaron M Teitelbaum; Alicia M Flaker; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-27       Impact factor: 3.205

4.  zzm321990 zzm321990 Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.zzm321990 zzm321990

Authors:  Brandon T Gufford; Ingrid F Metzger; Nadia O Bamfo; Eric A Benson; Andrea R Masters; Jessica Bo Li Lu; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2022-07-07       Impact factor: 4.402

5.  Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

Authors:  Andrea R Masters; Michael McCoy; David R Jones; Zeruesenay Desta
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-18       Impact factor: 3.205

6.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

7.  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Authors:  Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

8.  Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.

Authors:  Aaron M Teitelbaum; Alicia M Flaker; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-05-24       Impact factor: 3.205

9.  Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites.

Authors:  Emily E Fay; Lindsay C Czuba; Jennifer E Sager; Sara Shum; Alyssa Stephenson-Famy; Nina Isoherranen
Journal:  Ther Drug Monit       Date:  2021-12-01       Impact factor: 3.681

10.  Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.

Authors:  Jennifer E Sager; Lauren S L Price; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2016-08-05       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.